Aurobindo Pharma Hits 52-Week High of Rs 1,739: What's Driving the Stock Today

Published: 21 September 2026 at 9:48 AM IST

Aurobindo Pharma Share Price was Rs 1,734.30 on 21 September 2026 at 9:48 AM IST, down 0.04% from the previous close of Rs 1,735 after touching a fresh 52-week high of Rs 1,739 during the session. The company’s market capitalisation stood at Rs 99,828.06 crore. This Aurobindo Pharma Share Price update matters because it confirms a new one-year high in the stock’s live trade data, while the supplied numbers also show where the price stands relative to the day’s range and the broader valuation backdrop.

The move places Aurobindo Pharma Stock News firmly among stocks in news for the Indian stock market session. The opening level was Rs 1,713.45, the day low was Rs 1,708, and the day high matched the 52-week high at Rs 1,739. Turnover stood at Rs 3.59 crore. The supplied data confirms the price event, but it does not establish a company-specific catalyst. For readers tracking Aurobindo Pharma Share Price Today, the key point is that the stock has printed a fresh yearly high while ending just below that level at the time of capture.

Aurobindo Pharma Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,734.3
Previous Close	Rs 1,735
Today's Move	Rs -0.7 (-0.04%)
Open	Rs 1,713.45
High	Rs 1,739
Low	Rs 1,708
Turnover	Rs 3.59 crore
Market Capitalisation	Rs 99,828.06 crore

Aurobindo Pharma Ltd. (AUROPHARMA) traded at Rs 1,734.3 versus the previous close of Rs 1,735, a fall of 0.04%. The stock opened at Rs 1,713.45, reached a high of Rs 1,739 and touched a low of Rs 1,708.

Aurobindo Pharma Share Price today showed a narrow finish around the session high. The stock closed at Rs 1,734.30 versus the previous close of Rs 1,735, a day change of Rs -0.70 or -0.04%. The day open was Rs 1,713.45 and the day low was Rs 1,708, which kept the trade above the lower end of the session range. The day high of Rs 1,739 matched the 52-week high, making this a fresh 52-week high event in live data. Turnover of Rs 3.59 crore provides the traded-value context for the move, while the price action itself shows the stock finishing just below the session peak.

For Aurobindo Pharma Share Price Live readers, the immediate takeaway is straightforward: the stock touched a fresh 52-week peak, then settled slightly below it by the time the data was recorded. That is the central event in today’s Aurobindo Pharma Share Price movement and the reason Aurobindo Pharma Latest News is drawing search interest across NSE and BSE trackers.

Aurobindo Pharma Ltd. (AUROPHARMA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 99,828.06 crore
P/E Ratio	26.89x
P/B Ratio	2.56x
ROE	9.93%
ROCE	12.76%
EPS	Rs 64.52
Book Value Per Share	Rs 676.49
Dividend Yield	0.23%

Aurobindo Pharma Ltd. (AUROPHARMA) fundamental metrics show P/E 26.89x, P/B 2.56x, ROE 9.93%, ROCE 12.76%. These figures provide context only and are not a buy or sell signal.

Aurobindo Pharma Ltd. has a market capitalisation of Rs 99828.06 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 26.89x, P/B at 2.56x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 9.93% and ROCE of 12.76%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 64.52, book value per share of Rs 676.49, dividend yield of 0.23%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.9x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	26.89x
Benchmark Median P/E	32.9x
Benchmark Average P/E	48.91x
Benchmark P/E Range	3.4x to 683.5x
Company P/B Ratio	2.56x
Benchmark Median P/B	3.08x
Company ROE	9.93%
Benchmark Median ROE	11.7%
Company ROCE	12.76%
Benchmark Median ROCE	13.61%
Company Market Capitalisation	Rs 99,828.06 crore
Benchmark Median Market Cap	Rs 677.56 crore

Aurobindo Pharma Ltd. (AUROPHARMA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Aurobindo Pharma Ltd. (AUROPHARMA) has a P/E ratio of 26.89x, which is below the benchmark median of 32.9x, a difference of -18.27%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Aurobindo Pharma Ltd. (AUROPHARMA) has a ROE of 9.93%, which is below the benchmark median of 11.7%, a difference of -15.13%. Aurobindo Pharma Ltd. (AUROPHARMA) has a ROCE of 12.76%, which is below the benchmark median of 13.61%, a difference of -6.25%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Lupin Ltd.	LUPIN	98,069.81	17.74	4.12	27.11	28.86
Dr. Reddy's Laboratories Ltd.	DRREDDY	97,749.41	30.34	2.56	11.69	13.75
Mankind Pharma Ltd.	MANKIND	95,743.85	46.87	5.69	12.69	13.24
Laurus Labs Ltd.	LAURUSLABS	1,05,644.55	96.62	18.73	18.31	18.2
Cipla Ltd.	CIPLA	1,10,793.75	32.87	3.15	11.83	16

Aurobindo Pharma Ltd. (AUROPHARMA) has a P/E ratio of 26.89x compared with the displayed peer median of 32.87x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 9.93% compares with a peer median of 12.69% across the companies shown in the table. ROCE stood at 12.76% versus the displayed peer median of 16%, providing a capital-efficiency comparison. Aurobindo Pharma Ltd. (AUROPHARMA) has a market capitalisation of Rs 99,828.06 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching Aurobindo Pharma

• Aurobindo Pharma Share Price touched Rs 1,739, which is the fresh 52-week high in the supplied session data.
• The stock closed at Rs 1,734.30, just below the day high and just under the previous close of Rs 1,735.
• Market capitalisation stood at Rs 99,828.06 crore, with P/E at 26.89 and P/B at 2.56.
• ROE was 9.93% and ROCE was 12.76%, both measurable against the industry benchmark.
• Revenue and net profit both increased in the supplied year-on-year figures from Jun 2025 to Jun 2026.

About Aurobindo Pharma

Aurobindo Pharma Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied company financials show revenue of Rs 91,503.5 crore for Jun 2026 and net profit of Rs 10,325.6 crore for the same period. The share also carries EPS of Rs 64.52, book value of Rs 676.49 and dividend yield of 0.23% in the supplied dataset. These figures help place the Aurobindo Pharma Share Price within a basic company overview and financial context.

Track Aurobindo Pharma Share Price on Univest

Use Aurobindo Pharma Ltd. (AUROPHARMA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

You can track Aurobindo Pharma Share Price on Univest for live price updates, 52-week levels, shareholding pattern, financial ratios, market capitalisation, peer comparison and company insights. Univest also helps readers follow Aurobindo Pharma Share Price Today, Aurobindo Pharma Stock News and Aurobindo Pharma Share Price Live in one place.

For readers searching Aurobindo Pharma Latest News, Aurobindo Pharma Share News or Aurobindo Pharma Stock Performance, Univest combines market data with structured analysis so the fresh 52-week high can be viewed alongside valuation and sector context. That makes the Aurobindo Pharma Share Price easier to monitor across stock updates, market news and broader Indian stock market tracking.

Frequently Asked Questions

What is Aurobindo Pharma Share Price today?

Ans. Aurobindo Pharma Share Price was Rs 1,734.30 at the captured time, down 0.04% from the previous close of Rs 1,735. The stock also touched a fresh 52-week high of Rs 1,739 during the session.

Did Aurobindo Pharma hit a fresh 52-week high today?

Ans. Yes. Aurobindo Pharma touched Rs 1,739, which is the fresh 52-week high in the supplied data. The stock later traded slightly lower at Rs 1,734.30, but the yearly high remained intact in session data.

What is Aurobindo Pharma’s market cap?

Ans. Aurobindo Pharma’s market capitalisation is Rs 99,828.06 crore. That figure places the company far above the industry median in the supplied same-industry benchmark and helps frame the stock’s current valuation context.

What is Aurobindo Pharma’s P/E ratio?

Ans. Aurobindo Pharma’s P/E ratio is 26.89. In the same-industry snapshot, this is below the median of 32.9 and below the average of 48.91, giving a useful valuation reference point. The company trades at a P/E ratio of 26.89x.

What is Aurobindo Pharma’s P/B ratio?

Ans. Aurobindo Pharma’s P/B ratio is 2.56. The same-industry median is 3.08, so the stock is below that benchmark on book-value-based valuation in the supplied data set. The company trades at a P/E ratio of 26.89x.

What are Aurobindo Pharma’s ROE and ROCE?

Ans. Aurobindo Pharma reports ROE of 9.93% and ROCE of 12.76%. Both are close to the industry averages and below the corresponding same-industry medians in the supplied benchmark snapshot. ROE stands at 9.93%.

How do revenue and profit compare in Aurobindo Pharma’s latest figures?

Ans. Revenue rose from Rs 78,681.4 crore in Jun 2025 to Rs 91,503.5 crore in Jun 2026, while net profit increased from Rs 8,247.5 crore to Rs 10,325.6 crore over the same period.

What is Aurobindo Pharma’s EPS and book value?

Ans. EPS is Rs 64.52 and book value is Rs 676.49 per share. These figures help explain the Aurobindo Pharma Share Price alongside earnings and accounting net worth in the supplied data.

How does Aurobindo Pharma compare with peers?

Ans. Against the supplied peer set, Aurobindo Pharma sits near the middle on P/E and P/B, while peers like Lupin show stronger ROE and ROCE. Cipla and Zydus Lifesciences also carry different valuation and return profiles.